Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 11, 2019

Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time

Valentina Sarli , Laura Ciofi , Marianna Lastella , Beatrice Muscatello , Fioravante Pisaturo , Ombretta Paolilli , Giacomo Luci EMAIL logo , Federico Cucchiara , Giovanni Pellegrini , Guido Bocci , Romano Danesi and Antonello Di Paolo

Corresponding author: Giacomo Luci, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy, Phone: +39-050-2218755, Fax: +39-050-996477
aValentina Sarli and Laura Ciofi contributed equally to this work.
  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Plebani M. Foreword. Clin Chim Acta 2003;333:113.10.1016/S0009-8981(03)00174-8Search in Google Scholar

2. Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS One 2013;8:e78962.10.1371/journal.pone.0078962Search in Google Scholar

3. Al Za’abi M, Al Muqbali J, Al-Waili K. Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman. Saudi Pharm J 2015;23:458–62.10.1016/j.jsps.2014.11.005Search in Google Scholar

4. Boast A, Curtis N, Cranswick N, Gwee A. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother 2016;71:2031–6.10.1093/jac/dkw056Search in Google Scholar

5. Seng JJ, Yong MH, Peh ZX, Soong JL, Tan MH. Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore. Int J Clin Pharm 2018;40:977–81.10.1007/s11096-018-0670-4Search in Google Scholar

6. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014;69:1162–76.10.1093/jac/dkt508Search in Google Scholar

7. Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents 2013;42:250–5.10.1016/j.ijantimicag.2013.06.006Search in Google Scholar

8. Di Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. Clin Infect Dis 2014;58:1788–9.10.1093/cid/ciu230Search in Google Scholar

9. Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob 2017;16:60.10.1186/s12941-017-0235-8Search in Google Scholar

10. Carroll DJ, Austin GE, Stajich GV, Miyahara RK, Murphy JE, Ward ES. Effect of education on the appropriateness of serum drug concentration determination. Ther Drug Monit 1992;14:81–4.10.1097/00007691-199202000-00014Search in Google Scholar

Received: 2019-04-23
Accepted: 2019-05-19
Published Online: 2019-06-11
Published in Print: 2019-11-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 9.12.2022 from https://www.degruyter.com/document/doi/10.1515/cclm-2019-0429/html
Scroll Up Arrow